

Predictors of Incident Seizure in Systemic Lupus Erythematosus

XiangYang Huang, Laurence S. Magder, and Michelle Petri

ABSTRACT. Objective. The risk factors for incident seizures in systemic lupus erythematosus (SLE) were prospectively determined in a cohort study.

Methods. A total of 2203 patients with SLE followed longitudinally in the Hopkins Lupus Cohort were analyzed. Demographic variables, clinical manifestations, laboratory tests, and SLE disease activity were recorded at each quarterly visit. Adjusted estimates of association of risk factors for onset of seizure were derived using pooled logistic regression. We examined incident seizures in 3 ways: at the time of diagnosis, more than 45 days after the diagnosis of SLE, and after cohort entry.

Results. Of 2203 patients with no history of seizure prior to SLE diagnosis, 157 (7.13%) had the first seizure occurrence at the time of (37 patients, 1.68%) or after diagnosis (120 patients, 5.45%) of SLE. The risk of seizure occurring around the time of SLE diagnosis was higher in patients with a history of malar rash ($p = 0.002$), proteinuria ($p = 0.004$), and psychosis ($p < 0.001$). Multivariable analysis of the first seizure occurring after the diagnosis of SLE showed that history of low C3 ($p = 0.0078$), psychosis ($p < 0.0001$), cranial or peripheral neuropathy ($p = 0.0043$), anti-Sm antibody ($p = 0.0551$), renal involvement ($p = 0.0177$), and current corticosteroid dose ($p < 0.0001$) were independently associated with a higher incidence of seizure. Disease activity was not predictive after adjusting for corticosteroids.

Conclusion. Risk of seizure after diagnosis of SLE is increased in those patients with prior psychosis, neuropathy, proteinuria, anti-Sm, low C3, and use of corticosteroids. (J Rheumatol First Release January 15 2016; doi:10.3899/jrheum.150135)

Key Indexing Terms:

SYSTEMIC LUPUS ERYTHEMATOSUS

RISK FACTORS

SEIZURES

Seizures occur in many patients with systemic lupus erythematosus (SLE)^{1,2,3,4,5} and contribute to damage accrual². The first symptomatic seizure in SLE can occur either around the time of (32%) or after (68%) SLE onset². After the initial seizure, 12% to 43% experience recurrence³, mostly in the first year.

Seizures can be a primary event resulting from the direct effect of active SLE on the nervous system, but they may also be a secondary event due to stroke, hypertension (HTN), electrolytic disturbance, uremia, infection, or treatment. Studies have found that seizure was associated with early disease onset², male sex³, younger age², and African⁵ or African American ethnicity². Patients with SLE who develop

seizure seem to have shorter disease duration⁴, higher SLE disease activity^{2,3,5,6}, damage accrual^{2,3}, and a higher frequency of other neuropsychiatric disorders³, especially psychosis^{3,4,6} and stroke^{3,4,7}. Certain clinical nonneuropsychiatric features have been found to be associated with seizure, including cutaneous vasculitis^{2,3}, serositis⁴, and renal involvement^{2,4}. Mucocutaneous manifestations were also found to be protective (i.e., a longer time-to-seizure occurrence)². Some studies have suggested a high prevalence of antiphospholipid antibodies (aPL)^{3,8}, anti-Sm antibody³, autoantibodies to ribosomal P proteins (anti-P)^{9,10}, anti-neuronal antibodies¹¹, or brain reactive autoantibodies¹² in patients with SLE with seizure. A lower risk of seizure was found with anti-La¹³. The current use of oral corticosteroids^{2,5} and use of intravenous glucocorticoids⁴ or cyclophosphamide⁴ have been associated with seizure. Average dose of glucocorticoids and use of cyclophosphamide were associated with a shorter time-to-seizure occurrence². Although chloroquine^{14,15,16,17,18,19,20} was associated with seizure in the general population, 2 studies showed a protective effect of hydroxychloroquine (HCQ) against seizure occurrence in SLE^{2,5}.

To further elucidate the risk factors for seizure in patients with SLE, we determined the clinical and laboratory predictors associated with occurrence of first seizure in a large SLE cohort with longitudinal multivariable regression analysis.

From Sichuan University, West China School of Medicine, West China Hospital, Chengdu, Sichuan, P.R. China; Department of Rheumatology, University of Maryland School of Medicine; and Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland, USA.

Supported by a grant from the US National Institutes of Health (NIH AR 43727) and by grant number UL1 RR 025005 from the National Center for Research Resources.

X.Y. Huang, MD, PhD, Associate Professor, Sichuan University School of Medicine, West China Hospital; L.S. Magder, MPH, PhD, Professor of Epidemiology and Public Health, University of Maryland School of Medicine; M. Petri, MD, MPH, Professor of Medicine, Johns Hopkins University School of Medicine, Division of Rheumatology.

Address correspondence to Dr. M. Petri, Professor of Medicine, Division of Rheumatology, 1830 East Monument St., Suite 7500, Baltimore, Maryland, 21205, USA. E-mail: mpetri@jhmi.edu.

Accepted for publication August 28, 2015.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.

MATERIALS AND METHODS

Patients and study design. This analysis is based on the Hopkins Lupus Cohort (since 1987). The study was approved on a yearly basis by the Johns Hopkins University School of Medicine Institutional Review Board. All patients gave written informed consent. Data on demographic variables, clinical manifestations, laboratory tests, treatment, and comorbidities were obtained from the medical records of the patient at cohort entry and updated on standard forms at every quarterly visit.

At each quarterly clinic visit, manifestations, treatment, and laboratory measures were comprehensively evaluated. Clinical assessment of disease activity and damage was ascertained using the physician's global assessment (PGA)²¹, SELENA-SLEDAI (Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index)²² and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI)²³. Comorbidities were also noted [diabetes mellitus (intake of oral hypoglycemic agents and/or insulin) and HTN (recording of 3 abnormal readings and/or use of antihypertensive medications)].

Neuropsychiatric (NP) manifestations and seizures attributed to SLE were defined according to the ACR nomenclature and case definitions for NP-SLE syndromes²⁴. Seizure related to HTN, uremia, infection, diabetes mellitus, or electrolytic abnormalities was excluded. However, those patients with well-controlled HTN or diabetes were included in the analysis. Data on seizures were obtained from the medical records of each patient at cohort entry. The cohort database did not include the subtype of seizure. All patients were treated with antiseizure medicines after first seizure. Patients with SLE with proteinuria attributed to SLE were included. Renal biopsy was performed in those with ongoing proteinuria > 500 mg.

Statistical analysis. Three analyses of incident seizure were performed.

First, we explored the factors associated with having an incident episode of seizures at about the time of SLE diagnosis. The time of SLE diagnosis was set as the time period within 1 year before or within 45 days after the day of SLE diagnosis. We compared groups defined by clinical history with respect to the proportion with incident seizures at the time of diagnosis. Statistical significance was assessed using chi-square tests.

Second, we investigated factors associated with rates of new incidence of seizure occurring more than 45 days after SLE diagnosis; data were reformatted to consist of 1 record for every month after diagnosis for each patient. Each record contained the clinical history of the patient up until that time based on information from our retrospective history (if the month was before cohort entry) or from prospectively collected information (if the month was after cohort entry). Each person-month record also contained a variable indicating whether new seizure had occurred during that month. To estimate the association between clinical history and rates of seizure, each month was classified into a subgroup based on that predictor (e.g., age 18–39 yrs). Then we estimated the rate of new seizure per month in each subgroup by calculating the number of events of seizure divided by the number of person-months observed in that subgroup. Results were converted to rates per person-year. To assess whether associations between risk factors and rates of seizure persisted after controlling for potential confounding variable, we applied pooled logistic regression to the monthly data²⁵.

Third, we performed an analysis of predictors of incident seizures similar to the above analysis but restricting the analysis to followup that occurred during cohort participation. This restriction enabled us to look at predictors that were available only during cohort participation (e.g., SLE disease activity).

RESULTS

Demographic and clinical characteristics of included patients. There were 213 patients with a history of seizure among the total 2259 patients with SLE recruited in the cohort from June 1987 to June 2013. Fifty-six patients who had a history of seizure more than 1 year before diagnosis of

SLE were excluded from our analysis. Among the 2203 patients included in our analysis, patients were most frequently women (92.5%), with 82.5% less than 45 years old, and of multiple ethnicities (white 55% and African American 37.6%). Forty-six percent were followed up for more than 5 years. The SDI indicated minimal cumulative organ damage in patients, with 0 in 58%, 1 in 22%, 2–3 in 15%, and 4 or more in 5%, at cohort entry. The demographic characteristics, clinical manifestations, and laboratory tests are shown in Table 1.

Frequency of incident seizure. Among the 2203 patients with SLE without prior history of seizure, 157 patients (7.13%) had a first seizure occurrence at, or after, diagnosis. Of these, 37 patients (1.68%) had their first seizure at about the same time as diagnosis (within 1 yr before or 45 days after), while 120 patients (5.45%) had their first seizure more than 45 days after SLE diagnosis.

Predictors of seizure occurring around the time of SLE diagnosis. Considering the 37 patients who had the first seizure of SLE, we found that the likelihood of incident seizure at about the time of diagnosis was higher among patients with a history of malar rash ($p = 0.002$), proteinuria ($p = 0.004$), and psychosis ($p < 0.000$). Seizure at about the time of diagnosis was more likely among those with a history of serositis ($p = 0.037$; Table 1). The risk was somewhat higher among those with anti-Sm antibody, but not statistically significantly ($p = 0.097$; Table 1).

Demographic predictors of incident seizure occurring after SLE diagnosis. A total of 120 patients developed the first occurrence of seizure more than 45 days after diagnosis of SLE. As noted in Table 2, seizure onset was less likely in patients with higher income ($RR = 0.549$, $p = 0.046$), longer disease duration ($RR = 0.283$, $p = 0.002$), and recent calendar year ($RR = 0.524$, $p = 0.013$). Age, sex, ethnicity, education, smoking, and alcohol abuse history were not associated with seizure onset.

Clinical predictors of incident seizure after SLE diagnosis. A history of proteinuria was associated with new seizure onset ($RR = 1.61$, $p = 0.0092$; Table 2). As noted in Table 2, a history of many other neuropsychiatric manifestations was associated with a higher risk of seizures: specifically, psychosis ($RR = 3.688$, $p < 0.0001$), organic brain syndrome ($RR = 2.962$, $p = 0.0006$), aseptic meningitis ($RR = 2.44$, $p = 0.0505$), cerebrovascular disease ($RR = 1.609$, $p < 0.0001$), cranial or peripheral neuropathy ($RR = 2.015$, $p < 0.0001$), and cognitive impairment ($RR = 2.184$, $p = 0.0181$). A history of having an abnormal brain computerized tomographic (CT) scan ($RR = 2.150$, $p = 0.0156$) was associated with new seizure occurrence (Table 2).

We found that the onset of new seizure was associated with a history of anti-Sm antibody ($RR = 1.802$, $p = 0.0048$), low C3 ($RR = 1.958$, $p = 0.0011$), and low C4 ($RR = 1.676$, $p = 0.0064$).

Table 1. Risk of seizure occurring around the time of SLE diagnosis, by patient characteristic.

| Patient Characteristic | No. with Each Characteristic | No. (%) with Seizures | p |
|--|------------------------------|-----------------------|----------|
| Patients, n | 2203 | 37 (1.69) | |
| Sex | | | 0.164 |
| Female | 2038 | 32 (1.57) | |
| Male | 165 | 5 (3.03) | |
| Ethnicity | | | 0.351 |
| White | 1211 | 23 (1.9) | |
| African American | 830 | 10 (1.2) | |
| Asian | 162 | 4 (2.27) | |
| Age, yrs | | | 0.085 |
| < 29 | 1081 | 24 (2.22) | |
| 30–44 | 730 | 12 (1.64) | |
| 45–59 | 305 | 1 (0.33) | |
| 60+ | 78 | 0 (0.00) | |
| Single/married/other | | | 0.451 |
| Divorced | 242 | 2 (0.83) | |
| Married | 1215 | 21 (1.73) | |
| Single | 672 | 14 (2.08) | |
| Widowed | 51 | 0 (0.00) | |
| Income, US \$ | | | 0.011* |
| < 25,000 | 561 | 17 (3.03) | |
| 25–60,000 | 616 | 8 (1.30) | |
| 60–100,000 | 417 | 4 (0.96) | |
| 100,000+ | 355 | 2 (0.56) | |
| Education | | | 0.763 |
| < High school | 200 | 2 (1.00) | |
| High school | 536 | 11 (2.05) | |
| Some college | 587 | 11 (1.87) | |
| College + | 768 | 12 (1.56) | |
| Alcohol abuse | | | 0.664 |
| No | 2037 | 35 (1.67) | |
| Yes | 159 | 2 (1.71) | |
| Smoking history | | | 0.951 |
| No | 1375 | 23 (1.67) | |
| Yes | 820 | 14 (1.71) | |
| History of SLE — manifestations | | | |
| Malar rash | | | 0.002* |
| No | 1355 | 14 (1.03) | |
| Yes | 848 | 23 (2.71) | |
| Discoid rash | | | 0.149 |
| No | 1907 | 35 (1.84) | |
| Yes | 296 | 2 (0.68) | |
| Photosensitivity | | | 0.349 |
| No | 1297 | 19 (1.46) | |
| Yes | 906 | 18 (1.99) | |
| Oral ulcers | | | 0.524 |
| No | 1477 | 23 (1.56) | |
| Yes | 726 | 14 (1.93) | |
| Serositis | | | 0.037* |
| No | 1586 | 21 (1.32) | |
| Yes | 617 | 16 (2.59) | |
| Arthritis | | | 0.813 |
| No | 995 | 16 (1.61) | |
| Yes | 1205 | 21 (1.74) | |
| Renal disorder (urine protein +++) | | | 0.004* |
| No | 1862 | 21 (1.25) | |
| Yes | 521 | 16 (3.07) | |
| Neurologic criterion (including seizure and psychosis) | | | < 0.001* |
| No | 2123 | 1 (0.05) | |
| Yes | 80 | 36 (45) | |

Table 1. Continued.

| Patient Characteristic | No. with Each Characteristic | No. (%) with Seizures | p |
|------------------------|------------------------------|-----------------------|-------|
| Hematology disorder | | | 0.550 |
| No | 1325 | 24 (1.81) | |
| Yes | 878 | 13 (1.48) | |
| ANA | | | 0.270 |
| No | 70 | 0 (0) | |
| Yes | 2118 | 37 (1.70) | |
| Immunologic disorder | | | 0.609 |
| No | 1099 | 20 (1.82) | |
| Yes | 1104 | 17 (1.54) | |
| Anti-Sm | | | 0.097 |
| No | 1711 | 25 (1.46) | |
| Yes | 419 | 11 (2.63) | |
| Anti-dsDNA | | | 0.485 |
| No | 829 | 16 (1.93) | |
| Yes | 1368 | 21 (1.54) | |
| Anti-RNP | | | 0.143 |
| No | 1528 | 22 (1.44) | |
| Yes | 595 | 14 (2.35) | |
| Anti-Ro | | | 0.930 |
| No | 1465 | 25 (1.71) | |
| Yes | 665 | 11 (1.65) | |
| Anti-La | | | 0.394 |
| No | 1848 | 33 (1.79) | |
| Yes | 278 | 3 (1.08) | |
| Low C3 | | | 0.451 |
| No | 996 | 19 (1.91) | |
| Yes | 1204 | 18 (1.50) | |
| Low C4 | | | 0.894 |
| No | 1152 | 19 (1.65) | |
| Yes | 1045 | 18 (1.72) | |

* Statistically significant. SLE: systemic lupus erythematosus; ANA: anti-nuclear antibodies.

Predictors of incident seizure after the diagnosis of SLE in multivariable analysis. Based on the univariate results for the predictors in the 120 patients with seizure that occurred after SLE diagnosis, preliminary models were fit to assess which variables were most important. We found that low C4 was not significant after controlling for low C3. Anti-RNP and anti-Ro were not significant after controlling for anti-Sm antibody. Proteinuria and hematologic lupus were not statistically significant after adjustment for the other variables in the final model. Calendar year appeared important even after adjusting for other variables. We found that psychosis appeared by far to be the most important neurologic variable. Other neurologic manifestations, such as cognitive impairment, organic brain syndrome, lupus headache, aseptic meningitis, or abnormal brain CT scan were not statistically significant after controlling for psychosis.

Therefore, the final multivariable analysis included calendar year 2004 or later, low C3, anti-Sm antibody, psychosis, and cranial or peripheral neuropathy. After adjusting for all other variables in the model, we found that patients with anti-Sm antibody had a borderline higher rate

Table 2. The rate of having a first seizure more than 45 days after the time of SLE diagnosis, by patient characteristic.

| Subgroup | Observed No. Seizures | Person-years of Followup | Rate of Events per 1000 Person-years | Rate Ratios Based on a Model that Adjusts for Age (95% CI) | p |
|------------------------------|-----------------------|--------------------------|--------------------------------------|--|---------|
| All patients | 120 | 24,444 | 4.9 | | |
| Age, yrs | | | | | |
| < 29 | 69 | 13,518 | 5.1 | 1.0 (reference group) | |
| 30–44 | 32 | 7586 | 4.2 | 0.826 (0.54, 1.25) | 0.3727 |
| 45–59 | 18 | 2810 | 6.4 | 1.255 (0.74, 1.25) | 0.3907 |
| 60+ | 1 | 529 | 1.9 | 0.371 (0.05, 2.66) | 0.3240 |
| Sex | | | | | |
| F | 112 | 22,831 | 4.9 | 1.0 (reference group) | |
| M | 8 | 1613 | 5.0 | 1.011 (0.49, 2.07) | 0.9759 |
| Ethnicity | | | | | |
| African American | 49 | 9586 | 5.1 | 1.139 (0.78, 1.66) | 0.4986 |
| Asian | 11 | 1485 | 7.4 | 1.651 (0.87, 3.14) | 0.1265 |
| White | 60 | 13,372 | 4.5 | 1.0 (reference group) | |
| Education | | | | | |
| < high school | 15 | 2479 | 6.1 | 1.0 (reference group) | |
| High school | 27 | 6420 | 4.2 | 0.695 (0.37, 1.31) | 0.2585 |
| Some college | 37 | 6358 | 5.8 | 0.962 (0.52, 1.75) | 0.8987 |
| College+ | 32 | 8424 | 3.8 | 0.628 (0.34, 1.15) | 0.1367 |
| Income, US \$ | | | | | |
| < 25,000 | 43 | 7094 | 6.1 | 1.0 (reference group) | |
| 25–60,000 | 33 | 7088 | 4.7 | 0.768 (0.48, 1.21) | 0.2539 |
| 60–100,000 | 15 | 4505 | 3.3 | 0.549 (0.30, 0.98) | 0.0456* |
| 100,000+ | 13 | 3766 | 3.5 | 0.569 (0.31, 1.06) | 0.0752 |
| Smoking history | | | | | |
| No | 78 | 14,648 | 5.3 | 1.0 (reference group) | |
| Yes | 42 | 9796 | 4.3 | 0.805 (0.55, 1.17) | 0.2574 |
| Alcohol abuse | | | | | |
| No | 113 | 22,671 | 5.0 | 1.0 (reference group) | |
| Yes | 7 | 1772 | 3.9 | 0.792 (0.36, 1.70) | 0.5503 |
| Duration of SLE, yrs | | | | | |
| 0–3 | 50 | 5913 | 8.5 | 1.0 (reference group) | |
| 3–6 | 25 | 4864 | 5.1 | 0.607 (0.37, 0.98) | 0.0419* |
| 6–10 | 22 | 4996 | 4.4 | 0.521 (0.31, 0.85) | 0.0107* |
| 10–15 | 12 | 4083 | 2.9 | 0.347 (0.18, 0.65) | 0.0010* |
| 15+ | 11 | 4586 | 2.4 | 0.283 (0.14, 0.54) | 0.0002* |
| Calendar year | | | | | |
| 1987–1995 | 33 | 5124 | 6.4 | 1.0 (reference group) | |
| 1996–2004 | 49 | 8828 | 5.5 | 0.862 (0.55, 1.34) | 0.5089 |
| 2004–2013 | 27 | 7994 | 3.4 | 0.524 (0.31, 0.87) | 0.0129* |
| History of SLE manifestation | | | | | |
| Malar rash | | | | | |
| No | 57 | 11,889 | 4.8 | 1.0 (reference group) | |
| Yes | 63 | 12,554 | 5.0 | 1.047 (0.73, 1.49) | 0.8028 |
| Discoid rash | | | | | |
| No | 92 | 20,009 | 4.6 | 1.0 (reference group) | |
| Yes | 28 | 4434 | 6.3 | 1.374 (0.90, 2.09) | 0.1407 |
| Photosensitivity | | | | | |
| No | 59 | 12,155 | 4.9 | 1.0 (reference group) | |
| Yes | 61 | 12,289 | 5.0 | 1.023 (0.71, 1.46) | 0.9024 |
| Mucosal-ulcer | | | | | |
| No | 78 | 14,424 | 5.4 | 1.0 (reference group) | |
| Yes | 42 | 10,020 | 4.2 | 0.775 (0.53, 1.12) | 0.1832 |
| Arthritis | | | | | |
| No | 41 | 7649 | 5.4 | 1.0 (reference group) | |
| Yes | 79 | 16,794 | 4.7 | 0.878 (0.60, 1.28) | 0.4975 |
| Serositis | | | | | |
| No | 65 | 14,479 | 4.5 | 1.0 (reference group) | |
| Yes | 55 | 9965 | 5.5 | 1.230 (0.85, 1.76) | 0.2593 |

Table 2. Continued.

| Subgroup | Observed No. Seizures | Person-years of Followup | Rate of Events per 1000 Person-years | Rate Ratios Based on a Model that Adjusts for Age (95% CI) | p |
|----------------------------------|-----------------------|--------------------------|--------------------------------------|--|-----------|
| Urine protein | | | | | |
| No | 65 | 16,028 | 4.1 | 1.0 (reference group) | |
| Yes | 55 | 8417 | 6.5 | 1.610 (1.12, 2.31) | 0.0092* |
| Hematology disorder | | | | | |
| No | 48 | 11,675 | 4.1 | 1.0 (reference group) | |
| Yes | 72 | 12,768 | 5.6 | 1.372 (0.95, 1.97) | 0.0899 |
| Immunology disorder | | | | | |
| No | 41 | 9534 | 4.3 | 1.0 (reference group) | |
| Yes | 79 | 14,909 | 5.3 | 1.232 (0.84, 1.79) | 0.2780 |
| ANA | | | | | |
| No | 26 | 4542 | 5.7 | 1.0 (reference group) | |
| Yes | 94 | 19,901 | 4.7 | 0.825 (0.53, 1.27) | 0.3859 |
| Organic brain syndrome | | | | | |
| No | 109 | 23,638 | 4.6 | 1.0 (reference group) | |
| Yes | 11 | 806 | 13.6 | 2.962 (1.59, 5.5) | 0.0006* |
| Aseptic meningitis | | | | | |
| No | 115 | 24,016 | 4.8 | 1.0 (reference group) | |
| Yes | 5 | 427 | 11.7 | 2.440 (0.99, 5.9) | 0.0505* |
| Stroke | | | | | |
| No | 115 | 23,806 | 4.8 | 1.0 (reference group) | |
| Yes | 5 | 638 | 7.8 | 1.622 (0.62, 3.97) | 0.2896 |
| Cerebrovascular disease | | | | | |
| No | 112 | 23,404 | 4.8 | 1.0 (reference group) | |
| Yes | 8 | 1039 | 7.7 | 1.609 (0.78, 3.29) | < 0.0001* |
| Headache (lupus) | | | | | |
| No | 106 | 22,620 | 4.7 | 1.0 (reference group) | |
| Yes | 14 | 1824 | 7.7 | 1.638 (0.93, 2.86) | 0.0826 |
| Mononeuritis multiplex | | | | | |
| No | 118 | 24,243 | 4.9 | 1.0 (reference group) | |
| Yes | 2 | 201 | 9.9 | 2.045 (0.50, 8.27) | 0.3158 |
| Cranial or peripheral neuropathy | | | | | |
| No | 108 | 23,165 | 4.7 | 1.0 (reference group) | |
| Yes | 12 | 1278 | 9.4 | 2.015 (1.11, 3.65) | < 0.0001* |
| Cognitive impairment | | | | | |
| No | 110 | 23,467 | 4.7 | 1.0 (reference group) | |
| Yes | 10 | 977 | 10.2 | 2.184 (1.14, 4.17) | 0.0181* |
| Longitudinal myelitis | | | | | |
| No | 120 | 24,306 | 4.9 | 1.0 (reference group) | |
| Yes | 0 | 138 | 0.0 | < 0.001 (< 0.001, < 999.9) | 0.9805 |
| Psychosis | | | | | |
| No | 109 | 23,792 | 4.6 | 1.0 (reference group) | |
| Yes | 11 | 651 | 16.9 | 3.688 (1.98, 6.86) | < 0.0001* |
| Abnormal CT brain | | | | | |
| No | 109 | 23,348 | 4.7 | 1.0 (reference group) | |
| Yes | 11 | 1096 | 10.0 | 2.150 (1.15, 3.99) | 0.0156* |
| Abnormal MRI brain | | | | | |
| No | 104 | 21,502 | 4.8 | 1.0 (reference group) | |
| Yes | 16 | 2941 | 5.4 | 1.125 (0.66, 1.90) | 0.6617 |
| Fever | | | | | |
| No | 72 | 16,101 | 4.5 | 1.0 (reference group) | |
| Yes | 48 | 8343 | 5.8 | 1.287 (0.89, 1.85) | 0.1760 |
| Raynaud phenomenon | | | | | |
| No | 65 | 13,380 | 4.9 | 1.0 (reference group) | |
| Yes | 55 | 11,064 | 5.0 | 1.023 (0.73, 1.47) | 0.9001 |
| Vasculitis | | | | | |
| No | 109 | 21,702 | 5.0 | 1.0 (reference group) | |
| Yes | 11 | 2742 | 4.0 | 0.799 (0.43, 1.48) | 0.4774 |

Table 2. Continued.

| Subgroup | Observed No. Seizures | Person-years of Followup | Rate of Events per 1000 Person-years | Rate Ratios Based on a Model that Adjusts for Age (95% CI) | p |
|---------------------|-----------------------|--------------------------|--------------------------------------|--|---------|
| Sjögren syndrome | | | | | |
| No | 105 | 21,386 | 4.9 | 1.0 (reference group) | |
| Yes | 15 | 3057 | 4.9 | 1.000 (0.58, 1.71) | 1.0000 |
| Anti-dsDNA | | | | | |
| No | 34 | 8151 | 4.2 | 1.0 (reference group) | |
| Yes | 86 | 16,293 | 5.3 | 1.265 (0.85, 1.88) | 0.2453 |
| Anti-Sm | | | | | |
| No | 89 | 20,484 | 4.3 | 1.0 (reference group) | |
| Yes | 31 | 3960 | 7.8 | 1.802 (1.19, 2.71) | 0.0048* |
| Anti-Ro | | | | | |
| No | 77 | 17,451 | 4.4 | 1.0 (reference group) | |
| Yes | 43 | 6992 | 6.1 | 1.394 (0.96, 2.02) | 0.0807 |
| Anti-La | | | | | |
| No | 105 | 21,643 | 4.9 | 1.0 (reference group) | |
| Yes | 15 | 2800 | 5.4 | 1.104 (0.64, 1.89) | 0.7199 |
| Anti-RNP | | | | | |
| No | 83 | 18,491 | 4.5 | 1.0 (reference group) | |
| Yes | 37 | 5952 | 6.2 | 1.386 (0.94, 2.04) | 0.0990 |
| Anticardiolipin | | | | | |
| No | 57 | 11,578 | 4.9 | 1.0 (reference group) | |
| Yes | 63 | 12,866 | 4.9 | 0.995 (0.69, 1.42) | 0.9765 |
| Lupus anticoagulant | | | | | |
| No | 101 | 21,048 | 4.8 | 1.0 (reference group) | |
| Yes | 19 | 3396 | 5.6 | 1.600 (0.80, 3.10) | 0.5421 |
| Low C3 | | | | | |
| No | 32 | 10,164 | 3.1 | 1.0 (reference group) | |
| Yes | 88 | 14,280 | 6.2 | 1.958 (1.30, 2.93) | 0.0011* |
| Low C4 | | | | | |
| No | 44 | 12,038 | 3.7 | 1.0 (reference group) | |
| Yes | 76 | 12,406 | 6.1 | 1.676 (1.15, 2.43) | 0.0064 |

** Statistically significant; SLE: systemic lupus erythematosus; CT: computed tomography; MRI: magnetic resonance imaging; ANA: antinuclear antibody.

of seizure (RR = 1.518, p = 0.0551). Incidence of seizure declined within recent cohort years (RR = 0.680, p = 0.0826). Notably, history of low C3 (RR = 1.763, p = 0.0078), psychosis (RR = 2.432, p < 0.0001), and cranial or peripheral neuropathy (RR = 2.212, p = 0.0043) were independently associated with a higher risk of incident seizure (Table 3).

Predictors of incident seizure after cohort entry in univariate analysis. Of the 120 patients with seizures starting more than 45 days after SLE diagnosis, 56 occurred during cohort

participation. As noted in Table 4, the incidence of seizure onset significantly increased when the urine dipstick protein at the most recent visit was 3+ (RR = 7.4, p < 0.0001). The rate of incident seizure was 3.3 times higher in patients with SLE with higher current SLE disease activity as measured by a SELENA-SLEDAI score ≥ 5 versus 0 (RR = 3.349, p = 0.0004). The rate of incident seizure was 3.9 times higher in patients with SLE with a PGA score of 1.5 or more versus 0 (RR = 3.927, p < 0.0001; Table 4).

Table 3. Predictors of first seizure after SLE diagnosis based on a multivariate model.

| Variable | Comparison | Adjusted Rate Ratio (95% CI) | p |
|---|------------|------------------------------|----------|
| After 2004 | Yes vs no | 0.680 (0.440, 1.051) | 0.0826 |
| History of anti-Sm | Yes vs no | 1.518 (0.991, 2.327) | 0.0551 |
| History of low C3 | Yes vs no | 1.763 (1.161, 2.676) | 0.0078 |
| History of psychosis | Yes vs no | 2.432 (1.321, 4.477) | < 0.0001 |
| History of cranial or peripheral neuropathy | Yes vs no | 2.212 (1.208, 4.051) | 0.0043 |
| History of positive ANA | Yes vs no | 0.904 (0.578, 1.414) | 0.6585 |
| Year since SLE diagnosis | Per year | 0.923 (0.891, 0.956) | < 0.0001 |

ANA: antinuclear antibody; SLE: systemic lupus erythematosus.

Table 4. Rate of having a first seizure more than 45 days after time of SLE diagnosis during cohort participation, by time-varying risk factors.

| Subgroup | Observed No. Seizures | Person-years of Followup | Rate of Events per 1000 Person-years | Rate Ratios Based on Model that Adjusts for Age (95% CI) | p |
|--|-----------------------|--------------------------|--------------------------------------|--|-----------|
| Everyone | 56 | 13,747 | | | |
| Age group, yrs | | | | | |
| < 30 | 27 | 6707 | 4.0 | 1.0 (reference group) | |
| 30–44 | 17 | 4651 | 3.7 | 0.908 (0.495, 1.666) | 0.7552 |
| 45–59 | 11 | 2017 | 5.5 | 1.354 (0.672, 2.731) | 0.3965 |
| 60+ | 1 | 370 | 2.7 | 0.671 (0.091, 4.938) | 0.6951 |
| Duration of SLE, yrs | | | | | |
| 0–3 | 14 | 2251 | 6.2 | 1.0 (reference group) | |
| 3–6 | 14 | 2520 | 5.6 | 0.893 (0.426, 1.874) | 0.7656 |
| 6–10 | 15 | 3000 | 5.0 | 0.804 (0.388, 1.666) | 0.5572 |
| 10–15 | 6 | 2686 | 2.2 | 0.356 (0.138, 0.935) | 0.0359* |
| 15+ | 7 | 3288 | 2.1 | 0.342 (0.138, 0.848) | 0.0206* |
| Most recent (without seizure) SLEDAI | | | | | |
| None | 16 | 5093 | 3.1 | 1.0 (reference group) | |
| < 2 | 1 | 264 | 3.8 | 1.204 (0.160, 9.080) | 0.8573 |
| 2–5 | 19 | 5173 | 3.7 | 1.169 (0.601, 2.274) | 0.6449 |
| 5+ | 19 | 1807 | 10.5 | 3.349 (1.722, 6.513) | 0.0004* |
| Unknown | 1 | 1407 | 0.7 | 0.226 (0.030, 1.705) | 0.1493 |
| Mean SLEDAI (without seizure) in last 12 mos | | | | | |
| None | 6 | 1906 | 3.1 | 1.0 (reference group) | |
| < 2 | 7 | 3129 | 2.2 | 0.711 (0.239, 2.114) | 0.5391 |
| 2–5 | 10 | 3681 | 2.7 | 0.863 (0.314, 2.375) | 0.7754 |
| 5+ | 13 | 1208 | 10.8 | 3.420 (1.300, 8.999) | 0.0127* |
| Most recent physician's global assessment | | | | | |
| None | 13 | 4194 | 3.1 | 1.0 (reference group) | |
| 0–1 | 7 | 3821 | 1.8 | 0.591 (0.236, 1.482) | 0.2620 |
| 1–1.5 | 12 | 2436 | 4.9 | 1.589 (0.725, 3.484) | 0.2472 |
| 1.5+ | 23 | 1891 | 12.2 | 3.927 (1.989, 7.753) | < 0.0001* |
| Current prednisone, mg/day | | | | | |
| None | 9 | 6421 | 1.4 | 1.0 (reference group) | |
| 0–9 | 10 | 3328 | 3.0 | 2.144 (0.871, 5.276) | 0.0970 |
| 10–19 | 14 | 1793 | 7.8 | 5.572 (2.411, 12.876) | < 0.0001* |
| 20 | 22 | 761 | 28.9 | 20.668 (9.514, 44.899) | < 0.0001* |
| Mean prednisone in last 12 mos, mg/day | | | | | |
| None | 7 | 4598 | 1.5 | 1.0 (reference group) | |
| 1–9 | 11 | 3576 | 3.1 | 2.021 (0.783, 5.214) | 0.1457 |
| 10–19 | 15 | 1348 | 11.1 | 7.312 (2.981, 17.936) | < 0.0001* |
| 20+ | 6 | 326 | 18.4 | 12.108 (4.067, 36.045) | < 0.0001* |
| Current hydroxychloroquine | | | | | |
| No | 27 | 4143 | 6.5 | 1.0 (reference group) | |
| Yes | 28 | 8200 | 3.4 | 0.524 (0.309, 0.889) | 0.0166* |
| Mean current hydroxychloroquine in last 12 mos | | | | | |
| None | 14 | 2533 | 5.5 | 1.0 (reference group) | |
| Some | 9 | 1468 | 6.1 | 1.109 (0.480, 2.563) | 0.8087 |
| Always | 16 | 5880 | 2.7 | 0.492 (0.240, 1.009) | 0.0528* |
| Current immunosuppressant | | | | | |
| No | 34 | 8769 | 3.9 | 1.0 (reference group) | |
| Yes | 21 | 3575 | 5.9 | 1.515 (0.879, 2.611) | 0.1344 |
| Most recent urine protein dipstick | | | | | |
| < 3 | 41 | 11,693 | 3.5 | 1.0 (reference group) | |
| 3+ | 13 | 500 | 26.0 | 7.4 (4.0, 13.9) | < 0.0001 |

* Statistically significant; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index.

The rate of incident seizure increased significantly as the dose of current prednisone increased. Among those taking 10–19 mg/day, the rate of incident seizure was 5.6 times higher than the rate among those not taking prednisone (RR = 5.572,

$p < 0.0001$). Among those taking ≥ 20 mg per day, the rate was increased by a factor of 20.7 (RR = 20.668, $p < 0.0001$). The rate of incident seizure was 0.5 times lower in patients taking HCQ than the rate among those not taking HCQ (Table 4).

Table 5. Independent association between select predictors* and seizure onset based on those patients with SLE who developed seizure during cohort participation.

| Variables | Comparison | Adjusted Rate Ratio (95% CI) | p |
|----------------------------|----------------------|------------------------------|----------|
| Year since SLE diagnosis | Per year | 0.96 (0.92, 1.01) | 0.080 |
| Urine protein dipstick 3+ | Yes vs no | 2.74 (1.38, 5.44) | 0.0041 |
| Current SLEDAI > 4 | Yes vs no | 1.21 (0.66, 2.24) | 0.54 |
| Current prednisone, mg | 0–9 mg/day vs none | 1.75 (0.66, 4.60) | 0.26 |
| Current prednisone, mg | 10–19 mg/day vs none | 4.00 (1.61, 9.92) | 0.0028 |
| Current prednisone, mg | 20+ mg/day vs none | 11.77 (4.81, 28.81) | < 0.0001 |
| Current hydroxychloroquine | Yes vs no | 0.90 (0.50, 1.59) | 0.71 |

*In addition to predictors in this table, the model included predictors found significant in analysis of all postdiagnosis seizures including history of anti-Sm, low C3, psychosis, and neuropathy. SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index.

Multivariate analysis of the predictors of incident seizure after cohort entry (Table 5). The time-varying variables that appeared important based on analysis of the 56 patients with incident seizure during cohort participation were then combined. These included most recent SLEDAI ≥ 5 , current prednisone dose, current HCQ dose (200 mg twice daily), and urine dipstick protein. In multivariate analysis, the rate of incident seizure was 2.9 times higher in patients with urine dipstick protein positive 3+ versus none (RR = 2.74, $p = 0.0041$). We found that prednisone dose was very strongly associated with incident seizure. The incidence of new onset of seizure increased with the dose of current prednisone. HCQ was not protective after adjusting for the other variables in the model. High SELENA-SLEDAI was not a statistically significant predictor after adjusting for prednisone (RR = 1.2, $p = 0.54$). When the high mean SELENA-SLEDAI in the last 12 months was substituted in the model for most recent SELENA-SLEDAI, an elevated RR was found (RR = 1.5, 95% CI 0.7, 3.4); however, this finding was not statistically significant ($p = 0.27$).

DISCUSSION

Seizure affects about 1% of the general population²⁶. Seizure was among the most frequent neuropsychiatric syndromes in SLE, besides headache, mood disorders, and cognitive dysfunction^{27,29}. Hanly, *et al* found a cumulative frequency of 4.6% over a mean followup of 3.5 years in a cohort of 1631 patients with SLE⁵. Ramsey-Goldman, *et al*⁴ and Gonzalez-Duarte, *et al*²⁸ found that the frequency of incident seizures after SLE diagnosis (incident) was 6.2% in 1295 patients with SLE⁴ and 12.5% in 1200 patients with SLE over a mean of 5 years²⁸. In our cohort with 46% of patients followed up for more than 5 years, 7.13% had the first seizure occurrence at about the time of diagnosis of SLE (1.68%) or after (5.45%). The rate of incident seizure (among those with no prior seizure experience) was 4.9 per 1000 person-years. We found that 56 (26.3%) of 213 patients with a history of seizures had the first seizure occurrence more than 1 year before diagnosis of SLE. Of the 157 patients in our cohort

who developed seizure later, 24% developed seizures about the same time as their SLE diagnosis. Consistent with our findings, Appenzeller, *et al* found epileptic seizures occurred at the onset of SLE symptoms in 19 (31.6%) of SLE patients with seizures¹. We found that seizure onset was less likely in patients with longer disease duration. Consistently, another study found that 54% of incident seizure occurred within 1 year of SLE diagnosis²⁹. Therefore, although seizure can occur at any time — before, at, or after — SLE diagnosis, seizures have been a relatively early event in the disease course of SLE⁴.

“Calendar Year” refers to the year during which the followup occurred. We were interested in knowing whether the rates of incident seizure changed over time, so we estimated the rates of seizure over different time periods. We found that the incident rate of seizures in more recent calendar years had decreased. This finding may be the result of increased use of antimalarials. Although we did not find strong evidence that antimalarial use is protective, others have reported such findings^{2,5}. Antimalarial use is now virtually universal — and recently, blood levels are being measured to improve adherence.

African⁵ or African American ethnicity^{2,4}, younger age², and male sex³ have been associated with seizure. Both Hanly, *et al* and Ramsey-Goldman, *et al* found a high risk of seizure in African ethnicity⁵ and African American ethnicity⁴. However, this association was not confirmed in our larger study.

The incident seizure at about the time of diagnosis was higher among patients with a history of malar rash. In contrast, livedo reticularis and cutaneous vasculitis have been found to be associated with cerebrovascular accident and seizures²⁸.

We found that urine protein identified by dipstick of 3+ was statistically significantly associated with incident seizure after cohort entry. Several previous studies also found that renal involvement (particularly World Health Organization Class IV glomerulonephritis) was associated with a shorter time to seizure occurrence² and nephritis was associated with

seizure¹. Our findings using time-varying information strengthen the evidence for this association.

Seizure in SLE may occur in isolation or accompany other neurologic manifestations^{30,31}. Psychosis was noted to be associated with occurrence of seizure^{3,4,6} in several other SLE studies. Notably, we confirmed that history of psychosis was independently associated with a higher risk of incident seizure 45 days after the diagnosis of SLE. Antibodies against murine neuronal membrane proteins correlated with psychosis and/or seizures in 1 study of 100 patients with SLE¹², which might explain the association of psychosis with seizures. We also found an association of cranial or peripheral neuropathy with seizure in SLE. In the general population, a relationship between seizure and neuropathy has been recognized in familial cases^{32,33,34}.

Some studies have suggested a high prevalence of aPL^{3,8}, anti-Sm antibody³, anti-P^{9,10}, and antineuronal antibodies^{11,12} in patients with SLE with seizure. Notably, we found that anti-Sm antibody increased the risk of incident seizure both at the time of diagnosis of SLE and after. Anti-Sm antibody has also been associated with organic brain syndrome (encephalopathy) in patients with SLE³⁵ and schizophrenia in the general population. Reports have associated aPL with seizure in SLE^{1,3,36,37} due to thrombotic events or non-ischemic mechanisms³⁸. We did not find an association of seizure with aPL in SLE. Consistently, Hanly, *et al*⁵, Ramsey-Goldman, *et al* (which included Hopkins patients)⁴, and other studies^{39,40} reported no association between antiphospholipid positivity and seizures in patients with SLE. In non-SLE studies, it has not been clear whether aPL are⁴¹ or are not⁴² associated with seizure. However, a large study of 960 patients with epilepsy found no increase in anticardiolipin in non-SLE seizure patients versus controls⁴². We did not find a lower risk of seizures in patients with anti-La, in contrast to a previous report⁴³. We did not have data about anti-P^{9,10} or antineuronal antibodies^{11,12} because they are not routinely available and were not measured in our cohort.

Previous studies had shown that seizure occurred in patients with higher global SLE disease activity^{1,2,3}. However, previous reports did not control for corticosteroid use at the time of seizure onset. In univariate analysis, we found an association between SELENA-SLEDAI and seizure onset, but this association was reduced and not statistically significant after adjusting for corticosteroid dose at the time of seizure onset. This suggests that the association between disease activity and seizures might be due to greater use of corticosteroid dose among those with higher disease activity. However, because of the relatively small number of events in this analysis, the CI for the association between high SLEDAI and risk of seizures are wide and we cannot rule out an independent effect of high SLEDAI.

We found that a history of low C3 was independently associated with a higher risk of incident seizure after diagnosis of SLE. This indicates a role of serologic activity

in seizure occurrence. Low complement is included in the SLEDAI.

The current use of corticosteroids has been associated with increased risk of incident seizure⁵ and a shorter time-to-seizure². We found that prednisone dose was very strongly associated with incident seizure, and incidence of seizure increased with dose of current prednisone. This result persisted after adjusting for disease activity and was consistent with the studies of both Hanly, *et al*⁵ and Ramsey-Goldman, *et al*⁴. The association between prednisone and seizure is consistent with SLE global activity being a risk factor for seizure; but prednisone could also have an independent effect.

Antimalarials are neuroexcitatory and could decrease seizure threshold. In the general population, chloroquine^{14,15,16,17,18,19,20} has been associated with seizure. Hanly, *et al* found that antimalarials in the absence of immunosuppressive agents were associated with a reduced seizure risk⁵. The LUMINA cohort also reported that antimalarial therapy was protective for seizure occurrence in patients with SLE². However, we did not obtain strong evidence that HCQ was protective against seizure after adjustment for the other variables in the multiple variable models. This result was consistent with the study of Ramsey-Goldman, *et al*⁴, which included some of our patients.

In transgenic mice over-expressing interleukin 6 or tumor necrosis factor- α , a chronic inflammatory state in the brain predisposes to the occurrence of seizures and neuronal cell loss⁴⁴. Our findings on the association of low C3, anti-Sm antibody³, cutaneous activity (malar rash), lupus nephritis, and psychosis with seizure support an inflammatory mechanism in the onset of seizures in SLE.

Many previous studies were limited by small sample size, short duration of followup or cross-sectional design. The strength of our study is the large number of patients and the availability of clinical data roughly every 3 months during lengthy followup. We recognize the limitations of our study. We have examined only the first occurrence of seizure at or after SLE diagnosis. We did not have information on the subtypes of seizure that occurred or on followup seizures or anti-seizure treatment. We did not have data on anti-P or anti-neuronal antibodies.

Incident seizure at the time of diagnosis of SLE was associated with malar rash, psychosis, nephritis, and anti-Sm antibody. The risk of incident seizure after diagnosis of SLE was increased in those patients with psychosis, neuropathy, proteinuria, anti-Sm antibody, and low C3. Corticosteroid dose was strongly associated with incident seizure in models that included disease activity. These results may help clinicians identify patients at highest risk for seizures and provide useful information for guiding the evaluation of disease and therapy.

REFERENCES

1. Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. *Neurology* 2004;63:1808-12.
2. Andrade RM, Alarcon GS, Gonzalez LA, Fernandez M, Apte M, Vila LM, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). *Ann Rheum Dis* 2008;67:829-34.
3. Mikdashi J, Krumholz A, Handwerker B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. *Neurology* 2005;64:2102-7.
4. Ramsey-Goldman R, Alarcon GS, McGwin G, Petri M, Vila LM, Edberg JC, et al. Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort. *Lupus* 2008;17:177-84.
5. Hanly JG, Urowitz MB, Su L, Gordon C, Bae SC, Sanchez-Guerrero J, et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. *Ann Rheum Dis* 2012;71:1502-9.
6. Kapoor S. Commentary on: Predictive value of health-related quality of life in progression of disability and depression in persons with multiple sclerosis: a 3-year study. *Acta Neurol Belg* 2013;113:367.
7. Kargarfard M, Eetemadifar M, Mehrabi M, Maghzi AH, Hayatbakhsh MR. Fatigue, depression, and health-related quality of life in patients with multiple sclerosis in Isfahan, Iran. *Eur J Neurol* 2012;19:431-7.
8. Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. *J Rheumatol* 2003;30:985-92.
9. Sjonnesen K, Berzins S, Fiest KM, M Bulloch AG, Metz LM, Thombs BD, et al. Evaluation of the 9-item Patient Health Questionnaire (PHQ-9) as an assessment instrument for symptoms of depression in patients with multiple sclerosis. *Postgrad Med* 2012;124:69-77.
10. Stepleman LM, Decker M, Rollock M, Casillas R, Brands T. Depression screening in Black Americans with multiple sclerosis. *Psychol Health Med* 2014;19:33-9.
11. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis / chronic fatigue syndrome. *Neuro Endocrinol Lett* 2009;30:715-22.
12. Tin SK, Xu Q, Thumboo J, Lee LY, Tse C, Fong KY. Novel brain reactive autoantibodies: prevalence in systemic lupus erythematosus and association with psychoses and seizures. *J Neuroimmunol* 2005;169:153-60.
13. Dubayova T, Krokavcova M, Nagyova I, Rosenberger J, Gdovinova Z, Middel B, et al. Type D, anxiety and depression in association with quality of life in patients with Parkinson's disease and patients with multiple sclerosis. *Qual Life Res* 2013;22:1353-60.
14. Maes M, Maes L, Suy E. Symptom profiles of biological markers in depression: a multivariate study. *Psychoneuroendocrinology* 1990;15:29-37.
15. Maes M, Minner B, Suy E. The influences of dexamethasone levels on the predictive value of the DST for unipolar major depression and the relationships between post-dexamethasone cortisol and ACTH levels. *J Affect Disord* 1989;17:39-46.
16. Maes M, De Ruyter M, Claes R, Suy E. Sex-related differences in the relationships between self-rated depression and biological markers. *J Affect Disord* 1988;15:119-25.
17. Maes M, De Ruyter M, Claes R, Suy E. Self rated depression in relation to DSM-III classification: a statistical isolinear multiple components analysis. *Acta Psychiatr Scand* 1988;77:27-31.
18. Hellebuyck H, Maes M, Suy E. Repeated dexamethasone suppression test in major depression. *Acta Psychiatr Belg* 1988;88:378-86.
19. Maes M, De Ruyter M, Hobin P, Suy E. Relationship between the dexamethasone suppression test and the L-tryptophan/competing amino acids ratio in depression. *Psychiatry Res* 1987;21:323-35.
20. Maes MH, De Ruyter M, Suy E. Prediction of subtype and severity of depression by means of dexamethasone suppression test, L-tryptophan: competing amino acid ratio, and MHPG flow. *Biol Psychiatry* 1987;22:177-88.
21. Bol Y, Duits AA, Vertommen-Mertens CE, Hupperts RM, Romberg-Camps MJ, Verhey FR, et al. The contribution of disease severity, depression and negative affectivity to fatigue in multiple sclerosis: a comparison with ulcerative colitis. *J Psychosom Res* 2010;69:43-9.
22. Patten SB, Berzins S, Metz LM. Challenges in screening for depression in multiple sclerosis. *Mult Scler* 2010;16:1406-11.
23. Dresler M, Genzel L, Kluge M, Schussler P, Weber F, Rosenhagen M, et al. Off-line memory consolidation impairments in multiple sclerosis patients receiving high-dose corticosteroid treatment mirror consolidation impairments in depression. *Psychoneuroendocrinology* 2010;35:1194-202.
24. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. *Arthritis Rheum* 1999;42:599-608.
25. Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. *Q J Med* 1986;59:569-77.
26. Englot DJ, Chang EF. Rates and predictors of seizure freedom in resective epilepsy surgery: an update. *Neurosurg Rev* 2014;37:389-404.
27. Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. *Semin Arthritis Rheum* 2011;41:1-11.
28. Govoni M, Bombardieri S, Bortoluzzi A, Caniatti L, Casu C, Conti F, et al. Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. *Rheumatology* 2012;51:157-68.
29. González-Duarte A, Cantú-Brito CG, Ruano-Calderón L, García-Ramos G. Clinical description of seizures in patients with systemic lupus erythematosus. *Eur Neurol* 2008;59:320-3.
30. Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. *Neurology* 2002;58:1214-20.
31. Futrell N, Schultz LR, Millikan C. Central nervous system disease in patients with systemic lupus erythematosus. *Neurology* 1992;42:1649-57.
32. Wells DG. Folic acid and neuropathy in epilepsy. *Lancet* 1968;1:146.
33. Smith NJ, Espir ML, Matthews WB. Familial myoclonic epilepsy with ataxia and neuropathy with additional features of Friedreich's ataxia and peroneal muscular atrophy. *Brain* 1978;101:461-72.
34. Matsuoka T, Furuya H, Ikezoe K, Murai H, Ohyagi Y, Yoshiura T, et al. [A family with autosomal dominant temporal lobe epilepsy accompanied by motor and sensory neuropathy]. [Article in Japanese] *Rinsho Shinkeigaku* 2004;44:43-9.
35. Hirohata S, Kosaka M. Association of anti-Sm antibodies with organic brain syndrome secondary to systemic lupus erythematosus. *Lancet* 1994;343:796.
36. Shrivastava A, Dwivedi S, Aggarwal A, Misra R. Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with

- systemic lupus erythematosus: association with the presence of seizures. *Lupus* 2001;10:45-50.
37. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. *Arthritis Rheum* 1994;37:568-71.
 38. Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. *Life Sci* 1994;54:1119-25.
 39. Formiga F, Moga I, Canet R, Pac M, Mitjavila F, Pujol R. [Antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus]. [Article in Spanish] *Rev Clin Esp* 1996;196:734-6.
 40. Formiga F, Mitjavila F, Pac M, Moga I. Epilepsy and antiphospholipid antibodies in systemic lupus erythematosus patients. *Lupus* 1997;6:486.
 41. Stojanovich L, Kontic M, Smiljanic D, Djokovic A, Stamenkovic B, Marisavljevic D. Association between non-thrombotic neurological and cardiac manifestations in patients with antiphospholipid syndrome. *Clin Exp Rheumatol* 2013;31:756-60.
 42. Ranua J, Luoma K, Peltola J, Haapala AM, Raitanen J, Auvinen A, et al. Anticardiolipin and antinuclear antibodies in epilepsy—a population-based cross-sectional study. *Epilepsy Res* 2004;58:13-8.
 43. Malik S, Bruner GR, Williams-Weese C, Feo L, Scofield RH, Reichlin M, et al. Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. *Lupus* 2007;16:863-6.
 44. Samland H, Huitron-Resendiz S, Masliah E, Criado J, Henriksen SJ, Campbell IL. Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6. *J Neurosci Res* 2003;73:176-87.